Replies to post #12057 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Re: Priority review

Dr. Cox was mistaken and retracted the comments you cited on the 1Q08 CC in May (#msg-29148987, about 2/3 of the way down):

>>
The near-term events include, first of all, concluding an ATryn U.S. commercialization and development partner, and very importantly completing the filing of the U.S. heredity deficiency BLA early in the third quarter. Next, obtaining a determination of priority review status from the FDA, and supporting the FDA review timeline to reach a conclusion in early 2009.
<<